One-year follow-up data demonstrates sustained improvements across venous specific quality-of-life (...

One-year follow-up data demonstrates sustained improvements across venous specific quality-of-life (QoL) indicators. PMA application for the VenoValve submitted in November 2024, with an FDA decision expected in the second half of 2025.

NVNO

One-Year Data from the VenoValve(R) U.S. Pivotal Trial Highlighting Impact on Patients' Quality of Life (QOL) to be Presented Today at the 37th Annual Meeting of the American Venous Forum

One-year follow-up shows lasting improvements in venous specific QoL indicators.
FDA decision on VenoValve expected in H2 2025 may affect NVNO's market position.

one-year-data-from-the-venovalve-r-u-s-pivotal-trial-highlighting-impact-on-patients-quality-of-life-qol-to-be-presented-today-at-the-37th-annual-meeting-of-the-american-venous-forum

One-Year Data from the VenoValve(R) U.S. Pivotal Trial Highlighting Impact on Patients' Quality of Life (QOL) to be Presented Today at the 37th Annual Meeting of the American Venous Forum

FAQ

Why Bullish?

How important is it?

Why Long Term?

Related Companies

Related News